Journey Clinical
9 known investors
Journey Clinical provides ketamine-assisted psychotherapy (KAP) for depression, anxiety, and PTSD, partnering patients with licensed therapists and medical teams while coordinating with major insurance providers.
Investors · 9
Able PartnersNew York City · $500K – $3M
AlleyCorpNew York · $1M – $5M
Coalition OperatorsDover · $500K
Fifty YearsSan Francisco · $250K – $2M
Mantis CapitalSanta Monica · $100K – $1M
PROOFArlington
PsyMed VenturesBerkeley
Union Square Ventures (USV)New York · $1M – $20M
Alley Robotics VenturesreportedCohasset · $500K – $2Mvia Abe Murray · inferred
In the news
- Journey Clinical Raises $8.5M to Make the Benefits of Psychedelic-Assisted Therapies Accessible – AlleyWatchalleywatch.com · 2023
- Journey Clinical Raises $8.5M in Series A Fundingfinsmes.com · 2023
- Exclusive: Journey Clinical raises $9M to support psychedelic therapyaxios.com · 2023
- Journey Clinical's Series A | Union Square Venturesusv.com · 2023
- Journey Clinical raises $3M to allow psychotherapists to offer psychedelic therapies | TechCrunchtechcrunch.com · 2021